This is a community generated profile. If you would like to claim it, please
A growing body of scientific literature shows that protein isoforms correlate more precisely with disease state and patient-specific treatment response than current clinical biomarkers. Most protein isoforms (90%) are made by the body after the protein is produced (post-translational modifications). Such protein modifications remain largely inaccessible to current immunodiagnostic and nucleic acid clinical assays. Target Discovery's Isonostic™ products are designed to make this isoform biomarker information accessible to clinicians.